Gemphire Therapeutics Inc. (GEMP) financial statements (2021 and earlier)

Company profile

Business Address 200 BERKELEY ST.
BOSTON, MA 02116
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 14191824
Cash and cash equivalents 14191824
Restricted cash and investments 0   
Prepaid expense 0101
Deferred costs   0 
Other current assets 000 
Total current assets: 14201925
Noncurrent Assets
Property, plant and equipment 0   
Deposits noncurrent assets  000
Other undisclosed noncurrent assets 0   
Total noncurrent assets: 0000
TOTAL ASSETS: 14201925
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 2254
Accounts payable 1242
Accrued liabilities 1012
Debt  91 
Other undisclosed current liabilities 0   
Total current liabilities: 21264
Noncurrent Liabilities
Long-term debt and lease obligation   9 
Long-term debt, excluding current maturities   9 
Liabilities, other than long-term debt  000
Other liabilities  000
Other undisclosed noncurrent liabilities 0   
Total noncurrent liabilities: 0090
Total liabilities: 212154
Stockholders' equity
Stockholders' equity attributable to parent 128421
Common stock 0000
Additional paid in capital 49926448
Accumulated other comprehensive income 0   
Accumulated deficit (37)(84)(60)(27)
Total stockholders' equity: 128421
TOTAL LIABILITIES AND EQUITY: 14201925

Income statement (P&L) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Gross profit: (227)   
Operating expenses (20)(23)(33)(15)
Other undisclosed operating income 227   
Operating loss: (20)(23)(33)(15)
Nonoperating expense
(Other Nonoperating expense)
  (0)(0)(0)
Interest and debt expense (1)   
Loss from continuing operations before equity method investments, income taxes: (21)(23)(33)(15)
Other undisclosed income (loss) from continuing operations before income taxes (0)(1)(0)0
Loss from continuing operations before income taxes: (21)(24)(33)(15)
Income tax benefit 7   
Net loss: (14)(24)(33)(15)
Other undisclosed net loss attributable to parent (7)   
Net loss attributable to parent: (21)(24)(33)(15)
Preferred stock dividends and other adjustments    (0)
Net loss available to common stockholders, basic: (21)(24)(33)(15)
Interest on convertible debt    1
Net loss available to common stockholders, diluted: (21)(24)(33)(14)

Comprehensive Income ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss: (14)(24)(33)(15)
Comprehensive loss: (14)(24)(33)(15)
Other undisclosed comprehensive loss, net of tax, attributable to parent (7)   
Comprehensive loss, net of tax, attributable to parent: (21)(24)(33)(15)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: